Third, our approach: we'd rather under-treat and have you come back happy than over-treat and have you regret it
The SELECT cardiovascular outcomes trial demonstrated that semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in patients with obesity and established cardiovascular disease
Consistency in temperature is crucial
The GLP-1 pathway GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally produces after eating
Efficacy and effectiveness of incretin-based therapies in body weight reduction Randomized controlled trials (RCT) Liraglutide, titrated up to 3.0 mg administered subcutaneously once daily (OD), was the first incretin-based AOM to be developed and launched on the market
Mistake 6: reusing or sharing syringes This should be obvious, but it happens more than it should